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Background: Interactions between angina, blood pressure (BP), and coronary artery disease (CAD) are complex. Prior investigations have reported 
conflicting data on how these interactions affect mortality.
Methods: We performed a prespecified analysis of the INternational VErapamil/Trandolapril Study (INVEST) using extended follow-up data (9 years) 
from the United States (US) cohort to assess the impact of angina and BP on all-cause mortality.
Results: The extended US cohort included 17,131 patients with 4,047 deaths (23.6%). Angina was categorized as persistent (n=7,184), resolved 
(4,070), incident (899) or never (4,798) using standardized forms. BP was evaluated at baseline, during drug titration, and follow-up. On-treatment 
systolic BP was classified as tight (<130mmHg), controlled (≥130-<140mmHg), or uncontrolled (≥140mmHg). Both strategies contained an anti-
angina agent (atenolol or verapamil-SR) so doses of these drugs were evaluated. Unadjusted mortality per 1,000 patient-years was 35.59 for 
incident angina, 22.35 for persistent angina, 29.99 for resolved angina, and 39.28 for never angina (p < 0.0001). Unadjusted mortality rates per 
1,000 patient-years for the tight, controlled, and uncontrolled systolic BP categories were: 27.03; 26.55; and 39.58, respectively (p < 0.0001). 
Using a time-dependent Cox proportional hazards model (adjusted for age, heart failure, diabetes, renal impairment, myocardial infarction, stroke, 
smoking, and BP control), mortality was compared between the angina groups using the never angina group as control. We observed no difference 
in mortality for resolved (adjusted hazard ratio [HR] 0.98, 95% CI 0.90 to 1.07, p = 0.61) and incident (HR 0.89, 0.77 to 1.01, p = 0.075) 
angina groups. Persistent angina was associated with reduced mortality (HR 0.82, 0.75 to 0.89, p<0.0001) and higher doses of anti-angina drugs 
(p<0.001).
Conclusion: Among hypertensive CAD patients in the INVEST, presence or absence of angina is not a strong predictor of mortality risk after 
adjusting for other variables. Persistent angina was associated with reduced mortality, which could be related to ischemic preconditioning or 
increased use of anti-ischemic medications.
